HK1253572A1 - Pyrido-oxazinone derivatives as tnap inhibitors - Google Patents

Pyrido-oxazinone derivatives as tnap inhibitors

Info

Publication number
HK1253572A1
HK1253572A1 HK18112777.4A HK18112777A HK1253572A1 HK 1253572 A1 HK1253572 A1 HK 1253572A1 HK 18112777 A HK18112777 A HK 18112777A HK 1253572 A1 HK1253572 A1 HK 1253572A1
Authority
HK
Hong Kong
Prior art keywords
pyrido
tnap inhibitors
oxazinone derivatives
oxazinone
derivatives
Prior art date
Application number
HK18112777.4A
Other languages
Chinese (zh)
Inventor
Shojiro Miyazaki
Yuko Yamamoto
Keisuke Suzuki
Masaharu Inui
Masanori Izumi
Kaori Soma
Anthony Pinkerton
Taeko Shinozaki
Original Assignee
Daiichi Sankyo Co Ltd
Sanford Burnham Prebys Medical Discovery Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd, Sanford Burnham Prebys Medical Discovery Inst filed Critical Daiichi Sankyo Co Ltd
Publication of HK1253572A1 publication Critical patent/HK1253572A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK18112777.4A 2015-07-08 2018-10-08 Pyrido-oxazinone derivatives as tnap inhibitors HK1253572A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562190145P 2015-07-08 2015-07-08

Publications (1)

Publication Number Publication Date
HK1253572A1 true HK1253572A1 (en) 2019-06-21

Family

ID=57045381

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18112777.4A HK1253572A1 (en) 2015-07-08 2018-10-08 Pyrido-oxazinone derivatives as tnap inhibitors

Country Status (28)

Country Link
US (3) US9920068B2 (en)
EP (1) EP3319970B1 (en)
JP (1) JP6666928B2 (en)
KR (1) KR102590067B1 (en)
CN (1) CN107207527B (en)
AU (1) AU2016291163B2 (en)
CA (1) CA2962795C (en)
CO (1) CO2017003830A2 (en)
CY (1) CY1122477T1 (en)
DK (1) DK3319970T3 (en)
ES (1) ES2754480T3 (en)
HK (1) HK1253572A1 (en)
HR (1) HRP20192121T1 (en)
HU (1) HUE046994T2 (en)
IL (1) IL251005B (en)
LT (1) LT3319970T (en)
MX (1) MX2017003822A (en)
MY (1) MY185558A (en)
PH (1) PH12018500066A1 (en)
PL (1) PL3319970T3 (en)
PT (1) PT3319970T (en)
RS (1) RS59594B1 (en)
RU (1) RU2715704C2 (en)
SG (1) SG11201701378WA (en)
SI (1) SI3319970T1 (en)
TW (1) TWI702220B (en)
WO (1) WO2017007943A1 (en)
ZA (1) ZA201701783B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3045492C (en) * 2016-12-23 2021-10-19 Daiichi Sankyo Company, Limited Sulfonamide compounds having tnap inhibitory activity
WO2018119449A1 (en) * 2016-12-23 2018-06-28 Daiichi Sankyo Company, Limited Oxazepine derivatives having tnap inhibitory activity
JP7449283B2 (en) * 2018-10-23 2024-03-13 第一三共株式会社 biaryl derivative
CN114085911B (en) * 2022-01-19 2022-05-17 珠海圣美生物诊断技术有限公司 Method for detecting tumor cells or tumor cell fragments

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810795A (en) 1982-09-30 1989-03-07 A. H. Robins Company, Incorporated Certain 2,5 and 2,5,6-di- and tri-substituted nicotinic acid intermediates
WO2000032192A1 (en) 1998-11-27 2000-06-08 Takeda Chemical Industries, Ltd. Drugs
PE20011061A1 (en) * 2000-02-01 2001-11-20 Procter & Gamble SELECTIVE CRYSTALLIZATION OF 3-PYRIDYL-1-HYDROXY-ETHYLIDEN-1,1-BISPHOSPHONIC SODIUM ACID AS HEMIPENTAHYDRATE OR MONOHYDRATE
EP1910350A1 (en) 2005-07-09 2008-04-16 AstraZeneca AB 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
US8119693B2 (en) 2007-05-08 2012-02-21 Sanford-Burnham Medical Research Institute Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
US9458147B2 (en) 2012-02-22 2016-10-04 Sanford-Burnham Medical Research Institute Sulfonamide compounds and uses as TNAP inhibitors

Also Published As

Publication number Publication date
WO2017007943A1 (en) 2017-01-12
CA2962795C (en) 2019-09-10
MX2017003822A (en) 2017-06-26
EP3319970B1 (en) 2019-08-28
IL251005B (en) 2020-03-31
JP6666928B2 (en) 2020-03-18
LT3319970T (en) 2019-11-11
US10221195B2 (en) 2019-03-05
US20180141960A1 (en) 2018-05-24
PL3319970T3 (en) 2020-03-31
AU2016291163A1 (en) 2017-03-16
RS59594B1 (en) 2020-01-31
ES2754480T3 (en) 2020-04-17
KR102590067B1 (en) 2023-10-16
EP3319970A1 (en) 2018-05-16
CN107207527A (en) 2017-09-26
PH12018500066A1 (en) 2018-07-09
CO2017003830A2 (en) 2017-08-31
NZ729387A (en) 2023-12-22
IL251005A0 (en) 2017-04-30
SI3319970T1 (en) 2019-12-31
CA2962795A1 (en) 2017-01-12
RU2017117179A3 (en) 2019-09-24
US9920068B2 (en) 2018-03-20
HUE046994T2 (en) 2020-04-28
US20170240562A1 (en) 2017-08-24
ZA201701783B (en) 2018-12-19
HRP20192121T1 (en) 2020-02-21
RU2715704C2 (en) 2020-03-03
SG11201701378WA (en) 2018-01-30
CN107207527B (en) 2019-10-01
BR112017006798A2 (en) 2018-01-09
TW201713668A (en) 2017-04-16
RU2017117179A (en) 2019-08-08
TWI702220B (en) 2020-08-21
MY185558A (en) 2021-05-20
AU2016291163B2 (en) 2020-01-23
DK3319970T3 (en) 2019-12-02
JP2018522814A (en) 2018-08-16
US9879032B2 (en) 2018-01-30
CY1122477T1 (en) 2021-01-27
PT3319970T (en) 2019-11-15
KR20180028395A (en) 2018-03-16
US20170210755A1 (en) 2017-07-27

Similar Documents

Publication Publication Date Title
IL278916A (en) Benzoimidazole derivatives as pad4 inhibitors
PL3371190T3 (en) Heterocyclic compounds as pi3k-gamma inhibitors
IL246785A0 (en) Benzimidazol-2-amines as midh1 inhibitors
HK1226398A1 (en) Benzimidazol-2-amines as midh1 inhibitors
HK1251566A1 (en) Piperidine derivatives as hdac1/2 inhibitors
HRP20190127T1 (en) Pyrrolidinone derivatives as metap-2 inhibitors
IL246345A0 (en) 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
HK1232227A1 (en) Quinolizinone derivatives as pi3k inhibitors pi3k
HK1253572A1 (en) Pyrido-oxazinone derivatives as tnap inhibitors
HK1251572A1 (en) Triaza-spirodecanones as ddr1 inhibitors
IL252866B (en) Imidazopyridazine derivatives as pi3kbeta inhibitors
HK1252767A1 (en) Pyrazol-pyridine derivatives as eaat3 inhibitors
EP3526216C0 (en) Benzothiazole derivatives as dyrk1 inhibitors